ELMED Life Sciences Raises $2.7 Million to Expand Globally
India’s biotech sector is gaining serious momentum, and ELMED Life Sciences is the latest example of that growth.
The Hyderabad-based startup has raised $2.7 million (around Rs 25 crore) in a Series A funding round led by AgriSURE Fund, which is managed by NABVENTURES.
This fresh funding will help the company scale its operations, invest in research, and expand its reach both in India and internationally.
Where the Funds Will Be Used
Scaling Manufacturing and R&D
ELMED plans to use the capital to strengthen its manufacturing capabilities in Hyderabad. This will allow the company to produce more of its biological products efficiently and meet growing demand.
At the same time, the startup is investing heavily in research and development. This is a key focus area, as innovation in microbiome-based solutions requires continuous scientific advancement.
Expanding Market Reach
Another major priority is expanding distribution across India, especially in Tier 2 and Tier 3 markets. These regions represent a huge opportunity, particularly in agriculture and animal health.
Beyond India, ELMED is also working to build a stronger presence in global markets.
What Does ELMED Life Sciences Do?
A Focus on Microbiome-Based Solutions
Founded in 2018 by Pruthivin Reddy Madduri and Nikhil Konkathi, the company specializes in probiotic and biological solutions.
Its work is centered around microbiome technology, which uses beneficial microorganisms to improve health and productivity.
Multiple Industries, One Core Technology
ELMED’s products are used across several sectors, including:
- Animal health (poultry, dairy, livestock)
- Aquaculture
- Agriculture and soil health
- Human health supplements
This diversified approach allows the company to tap into multiple high-growth industries while leveraging the same core technology.
A Unique B2B Business Model
Powering Big Pharma Brands
ELMED operates primarily as a B2B company. Instead of selling directly to consumers, it manufactures products for other businesses.
According to co-founder Madduri, the company handles everything from formulation to supply. Its probiotic products are used by major pharmaceutical companies like Alchem and Hetero.
These companies then market the final products under their own brand names.
Strong Enterprise Client Base
In addition to pharma partnerships, ELMED supplies enterprise clients such as Aurobindo Pharma and Apex Laboratories.
This strong client base provides consistent demand and validates the company’s product quality.
Growing Global Footprint
Exporting to 18+ Countries
ELMED is not just focused on India. The company already exports its products to more than 18 countries.
This international presence highlights the global demand for sustainable biological solutions.
Next Stop: Europe, Asia, and Latin America
With the new funding, the startup aims to expand further into:
- Europe
- Asia
- Latin America
These markets offer significant opportunities, especially as industries shift toward eco-friendly and sustainable practices.
Why Investors Are Interested
The Shift Toward Sustainable Agriculture
One of the biggest drivers behind this investment is the global push for sustainable and residue-free agriculture.
Ashish Choudhary pointed out that Indian agriculture is steadily moving in this direction. Farmers and businesses are increasingly looking for alternatives to chemical-based solutions.
Biological products, like those developed by ELMED, play a crucial role in this transition.
The Bigger Picture: Rise of Biological Solutions
Moving Away from Chemicals
Across industries, there is a growing shift toward natural and biological alternatives.
Key reasons include:
- Environmental concerns
- Regulatory pressure
- Consumer demand for safer products
Microbiome-based technologies offer a promising solution by improving productivity without harming the ecosystem.
Opportunities Across Industries
The applications of such technologies are vast:
- Improving soil fertility
- Enhancing animal health
- Boosting aquaculture yields
- Supporting human gut health
This wide range of use cases makes companies like ELMED highly attractive to investors.
What’s Next for ELMED Life Sciences
Building a Global Biotech Brand
With fresh funding and a strong foundation, ELMED is entering its next phase of growth.
The company aims to:
- Expand production capacity
- Strengthen scientific research
- Grow its international footprint
- Reach more customers in underserved markets
Strengthening Its Market Position
By focusing on both innovation and distribution, ELMED is positioning itself as a key player in the global biotech space.
Its ability to serve multiple industries while maintaining a strong B2B model gives it a competitive edge.
Final Thoughts
ELMED Life Sciences is tapping into one of the most important trends of our time: the move toward sustainable, biology-driven solutions.
With strong investor backing, a growing global presence, and a clear focus on innovation, the startup is well on its way to becoming a significant player in the biotech industry.
As demand for eco-friendly and effective solutions continues to rise, companies like ELMED could shape the future of agriculture, healthcare, and beyond.
